Bausch + Lomb Corporation
Every calculator, already run for BLCO
Open the full toolkit →You have the numbers on BLCO. Get the argument.
A written report on which of these readings actually decide the outcome for Bausch + Lomb Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering BLCOAnalyst Price Target Disagreement for Bausch + Lomb Corporation
Wall Street's bull case implies +27% from the current price; the bear case implies -12%. A 39% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BLCO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such…
BLCO — frequently asked
Is BLCO a buy right now?
Wall Street's consensus rating on Bausch + Lomb Corporation is Buy across 15 analysts, with a mean price target of $21.14 (+4% vs. the current $20.40). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Bausch + Lomb Corporation?
Analysts covering Bausch + Lomb Corporation (BLCO) range from a bear-case target of $18.00 to a bull-case high of $26.00, with a mean consensus target of $21.14 across 14 analysts. The spread of $8.00 (39% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bausch + Lomb Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bausch + Lomb Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BLCO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bausch + Lomb Corporation, in minutes. 3 free reports included with every account — no credit card required.